Sitryx Therapeutics announced positive Phase 1a trial results for SYX-5219, an oral PKM2 modulator targeting atopic dermatitis. The trial in healthy volunteers showed the drug was safe, well tolerated, and demonstrated immune system modulation by reducing a key inflammation biomarker. This supports SYX-5219's potential as a disease-modifying oral therapy for atopic dermatitis. A Phase 1b trial in patients with severe atopic dermatitis is ongoing, with data expected by the end of 2026.
Viking Therapeutics reported that 74% of participants receiving weekly subcutaneous VK2735 improved by at least one BMI category after 13 weeks, with no patients experiencing BMI worsening. The Phase 2 VENTURE trial also showed significant improvemen...
In Q3 2026, AMG TimesSquare Small Cap Growth Fund outperformed the Russell 2000® Growth Index, driven by strong holdings in Information Technology, Financials, and Consumer Staples sectors. The fund's success was attributed to company-specific fundam...
The Schwab US Dividend Equity ETF (SCHD) has rallied about 10% since early October, supported by stronger earnings from key holdings like Texas Instruments and UnitedHealth, as well as inflows into dividend-focused funds. SCHD trades at roughly 18.6 ...
Helus Pharma will present topline results from its Phase 3 APPROACH study evaluating HLP003 as an adjunctive treatment for major depressive disorder on November 16, 2026. This drug has received Breakthrough Therapy Designation from the FDA, highlight...
Eaton Vance Tax-Advantaged Global Dividend Income Fund (ETG) raised its monthly distribution by 23.7%, marking its highest payout since inception. Despite this increase and strong long-term returns, ETG shares trade at a significant discount of over ...
